立体定向放射治疗 (SRT) 对脑转移的局部控制率很高，但农村/郊区患者在接受 SRT 方面面临地理和社会经济障碍。我们在一个综合学术卫星网络中针对 1-4 处脑转移的 18 岁以上患者进行了无框架分割立体定向放射治疗 (FFSRT) 脑转移的 2 期临床试验。剂量基于肿瘤总体积 (GTV) 大小：< 3.0cm，27Gy，分 3 次；3.0-3.9cm，30Gy，分 5 次。 73 名可评估患者的中位随访时间为 10 个月，中位年龄为 68 岁。中位颅内无进展生存期 (PFS) 为 7.1 个月（95% 置信区间 (CI)：5.3-未达到 (NR)），中位生存期为 7.2 个月（95% CI：5.4-NR），并且没有严重不良事件。该试验的结果与当代试验相比较，该治疗策略为将 SRT 扩大到服务不足的人群提供了机会。© 作者 2023。由牛津大学出版社出版。

Stereotactic radiotherapy (SRT) yields high rates of local control for brain metastases, but rural/suburban patients face geographic and socioeconomic barriers to access SRT. We conducted a Phase 2 clinical trial of frameless fractionated stereotactic radiotherapy (FFSRT) for brain metastases in an integrated academic satellite network for patients ≥18-years-old with 1-4 brain metastases. Dose was based on gross tumor volume (GTV) size: < 3.0 cm, 27 Gy in 3 fractions, and 3.0-3.9 cm, 30 Gy in 5 fractions. Median follow-up was 10 months for 73 evaluable patients with median age of 68 years. Median intracranial progression free survival (PFS) was 7.1 months (95% confidence interval (CI): 5.3-not reached (NR)), median survival 7.2 months (95% CI: 5.4-NR), and there were no severe adverse events. Outcomes of this trial compare favorably with contemporary trials and this treatment strategy provides opportunities to expand SRT access to underserved populations.© The Author(s) 2023. Published by Oxford University Press.